Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCOA3 | Q9Y6Q9 | 3/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.67 |
| ▸ | RRM2 | P31350 | 3/20 | 0.59 |
| ▸ | RRM1 | P23921 | 1/20 | 0.59 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.59 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | G6PD | P11413 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GUSB | P08236 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29773648 | 1.00 | NCOA3 (1.00) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL13927328 | 1.00 | NCOA3 (1.00) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL31237388 | 1.00 | NCOA3 (1.00) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL13380986 | 0.87 | NCOA3 (0.77) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL29773638 | 0.83 | NCOA3 (0.71) | NCOA3NCOA1RRM2MAPTGAA | |
| SCHEMBL29773611 | 0.82 | NCOA3 (0.70) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL29773626 | 0.82 | NCOA3 (0.70) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL29773644 | 0.81 | NCOA3 (0.68) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL29773649 | 0.81 | NCOA3 (1.00) | NCOA3NCOA1RRM2RRM1RRM2B | |
| SCHEMBL21649903 | 0.78 | NCOA3 (0.64) | NCOA3RRM1MAPTGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| US-8932617-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L (US) | 2015-01-13 | — | — | US | disclosed |
| US-20120329870-A1 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders | ELFORD HOWARD L (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8029815-B2 | Methods for treating or preventing restenosis and other vascular proliferative disorders | ELFORD HOWARD L | 2011-10-04 | — | — | US | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| WO-2008073961-A9 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | UNIV EMORY (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008073961-A2 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | EMORY UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | ELFORD HOWARD L | 2008-02-28 | — | — | US | disclosed |
| EP-1744761-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | Molecules for Health, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005115405-A1 | METHODS FOR TREATING OR PREVENTING RESTENOSIS AND OTHER VASCULAR PROLIFERATIVE DISORDERS | MOLECULES FOR HEALTH, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-6248782-B1 | ADMINISTERING ENZYME INHIBITOR | ELFORD HOWARD L (US) | 2001-06-19 | — | — | US | disclosed |
| US-6030942-A | TO TREAT CANCER AND VIRAL AND BACTERIAL INFECTIONS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-02-29 | — | — | US | disclosed |
| WO-1999048504-A1 | COMPOSITIONS FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS USING HYDROXYUREA AND A REVERSE TRANSCRIPTASE INHIBITOR | LISZIEWICZ JULIANNA (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998007716-A2 | HETEROAROTINOIDS-ANTICANCER AGENTS WITH RECEPTOR SPECIFICITY AND TGASE ACTIVITY | THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITY (US) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | NCOA3 2005/4885NCOA1 2036/4885RRM2 6/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | NCOA3 2005/4885NCOA1 2036/4885RRM2 6/4885 |
| US-20120071539-A1 | COMPOUNDS AND METHODS FOR MODULATING THE SILENCING OF A POLYNUCLEOTIDE OF INTEREST | SNRPE, NSUN2, SNRPA | NCOA3 477/4885NCOA1 763/4885RRM2 40/4885 |
| US-20120329870-A1 | Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | NCOA3 3044/4885NCOA1 3456/4885RRM2 3/4885 |
| US-20080050414-A1 | Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders | RRM2B, PCNA, RRM2 | NCOA3 3044/4885NCOA1 3456/4885RRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.